Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.
- FDA grants 510(k) clearance with CLIA waiver for FebriDx, expanding US addressable market to 80 million patients annually
- Milestone payments of US$6.2 million triggered from PHASE Scientific and BARDA
- Q3 FY26 revenue up 37% to US$4.8 million, driven by 243% growth in product sales
- A$20 million placement completed; Share Purchase Plan underway
- Delays in Hologic fFN project milestones push timeline to February 2027
FDA CLIA Waiver Transforms FebriDx Market Potential
Lumos Diagnostics (ASX:LDX) hit a major commercial milestone in Q3 FY26 with the US FDA granting 510(k) clearance alongside a Clinical Laboratory Improvement Amendments (CLIA) waiver for its flagship rapid diagnostic test, FebriDx®. This regulatory green light expands the test’s addressable US market to approximately 80 million patients annually, a fifteen-fold increase from its previous scope, and opens access to over 300,000 US healthcare locations including primary care offices, urgent care clinics, and retail pharmacies.
The CLIA waiver milestone unlocked substantial non-dilutive funding, with PHASE Scientific paying Lumos US$5 million and the Biomedical Advanced Research and Development Authority (BARDA) contributing another US$0.5 million. These payments arrived post-quarter, bolstering Lumos’ balance sheet and supporting the commercial rollout of FebriDx® across the US healthcare system.
This surge in commercial traction is exemplified by PHASE Scientific’s largest-ever purchase order of US$1.3 million placed shortly after the clearance, with product shipments contributing to the quarter’s revenue. The order follows a series of pre-payments under the exclusive distribution agreement valued at US$317 million over six years. The expanded rollout of FebriDx® at WellStreet Urgent Care’s network, growing from a single site to 44 locations, further underscores the test’s widening adoption. The program will extend across multiple Georgia districts and Michigan markets over the coming months.
Revenue Growth and Capital Raise Strengthen Position
Lumos reported a 37% year-on-year revenue increase to US$4.8 million in Q3 FY26, led by a 243% jump in product sales to US$2.4 million, primarily driven by FebriDx® volumes that offset the discontinued ViraDx® test. Services revenue declined 14% to US$2.4 million, impacted by a lower amortisation rate on the Hologic fFN IP license fee due to an extended project timeline.
The company’s cash position tightened to US$1.1 million at quarter-end, reflecting an operating cash outflow of US$2.8 million driven by inventory investments and increased operating expenses. However, Lumos swiftly reinforced its liquidity post-quarter with the receipt of the US$5 million PHASE milestone payment and proceeds from a A$20 million placement to institutional and sophisticated investors, completed in early April. The ongoing Share Purchase Plan, offering shares at A$0.225 with free attaching options, aims to raise additional funds by 24 April 2026, complementing the capital structure and funding growth initiatives.
These developments follow Lumos Diagnostics’ recent largest FebriDx® order, which validated the commercial potential unlocked by regulatory progress.
Development Pipeline Advances Amid Project Delays
On the development front, Lumos continues to progress multiple contracts, including the BARDA-funded paediatric FebriDx® clinical study aimed at expanding the test’s use to children aged 2 to 12 years. The study has triggered milestone payments totaling US$1.92 million to date, with further milestones expected upon study completion and FDA submissions.
The Hologic fFN diagnostic project, which involves adapting Hologic’s pre-term birth test to Lumos’ reader platform, faces delays. While Phase 2 assay feasibility work is nearing completion, Phase 3 system prototype milestones are postponed to February 2027, pushing out anticipated milestone payments of approximately US$3.4 million. This delay impacts the timing of future revenue recognition from this significant contract.
Additionally, Lumos secured follow-on contracts with Aptatek Biosciences to advance an in-home monitoring tool for phenylketonuria and a three-year manufacturing agreement with Micro-Pak for their Mold Analyzer system, reflecting diversification and growth in Lumos’ services and manufacturing divisions.
Bottom Line?
Lumos’ FDA CLIA waiver for FebriDx® unlocks a vastly larger US market and milestone payments that strengthen its cash position, but execution risks remain in clinical trials and development timelines.
Questions in the middle?
- How quickly will FebriDx® achieve widespread adoption and reimbursement across the expanded US market?
- What impact will the delay in Hologic’s fFN project have on Lumos’ near-term revenue and cash flow?
- Will the Share Purchase Plan meet its target, and how will this influence Lumos’ funding runway and operational flexibility?